
Sign up to save your podcasts
Or


In our fourth episode of the Portfolio Perspective we interview Joshua Shultz, CEO of Cytel, a company dedicated to shaping the future of drug development.
Join us as we discuss Cytel's experience working with private equity, the future of drug development, and how Cytel is helping in the global race to find a vaccine.
By Shruti Rao5
1515 ratings
In our fourth episode of the Portfolio Perspective we interview Joshua Shultz, CEO of Cytel, a company dedicated to shaping the future of drug development.
Join us as we discuss Cytel's experience working with private equity, the future of drug development, and how Cytel is helping in the global race to find a vaccine.